Discontinuation report BACITRACIN USP
Report ID | 135983 |
Drug Identification Number | 00030708 |
Brand name | BACITRACIN USP |
Common or Proper name | BACITRACIN USP |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | BACITRACIN |
Strength(s) | 50000UNIT |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAMUSCULAR TOPICAL INTRAMUSCULAR TOPICAL |
Packaging size | 5 x 30mL vial |
ATC code | J01XX |
ATC description | OTHER ANTIBACTERIALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2021-03-31 |
Remaining supply date | 2021-03-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2021-04-01 | English | Compare |
v2 | 2021-03-18 | French | Compare |
v1 | 2021-03-18 | English | Compare |
Showing 1 to 3 of 3